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Abstract
Prosthetic vascular graft infection (PVGI) is a devastating complication, with a mortality rate of up to 75%, which is especially caused by
aortic graft infection. The purpose of this study was to evaluate factors associated with in-hospital mortality of patients with definite
graft infection, and with long-term outcome. We reviewed medical records of 85 patients treated for PVGIs defined by positive bacte-
rial culture of intraoperative specimens or blood samples, and/or clinical, biological and radiological signs of infection. In-hospital patient
mortality was defined as any death occurring during the initial treatment of the graft infection. Cure was defined as the absence of evi-
dence of relapsing infection during long-term follow-up (‡1 year). Eighty-five patients (54 aortic and 31 limb graft infections) treated by
surgical debridement and removal of the infected prosthesis (n = 41), surgical debridement without removal of prosthesis (n = 34) or
antimicrobial treatment without surgery (n = 10) were studied. The only microbiological difference observed between patients with
early (occurring within 4 months after surgery) vs. late PVGI and between those with aortic vs. limb PVGI was the incidence of PVGI
caused by Staphylococcus aureus, which was greater in patients with limb PVGI. Overall cure was observed in 93.2% of 59 patients with
a follow-up of a minimum of 1 year. Overall in-hospital mortality was 16.5% (n = 14). Two variables were independently associated with
mortality: age >70 years (OR 9.1, 95% CI 1.83–45.43, p 0.007) and aortic graft infection (OR 5.6, 95% CI 1.1–28.7, p 0.037).
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Introduction
The occurrence of prosthetic vascular graft infection (PVGI)
is infrequent, with a cumulative incidence varying from 0.5%
to 5% [1,2].
Mortality rates up to 75% and limb amputation rates up
to 70% have been reported [3–9]. Although a combination
of clinical assessment with imaging and microbial investiga-
tions is usually helpful, no currently validated criteria exist
for defining PVGI. There is no general agreement on choice
of antimicrobial agents and duration of use. Removal of
infected material is strongly recommended in late PVGI
[2,7,8,10].
As suggested by FitzGerald et al. [2], we created in 2005 a
multidisciplinary group including vascular surgeons, microbiol-
ogists, infectious diseases physicians, anaesthesiologists and
intensivists to optimize the management of patients with
PVGI. Little by little, this group is taking in charge a growing
number of patients coming from hospitals and clinics of the
Nord-Pas de Calais area (4 million inhabitants) in the north
of France. This high number of patients with well-documen-
tated PVGI, treated in our referral centre (Infectious Dis-
eases and Vascular Surgery Departments of Lille and
Tourcoing hospitals) for a short period, gives us the oppor-
tunity to study variables associated with fatal outcome during
their hospital stay and to evaluate trhe outcome of survivors
after a minimum follow-up of 1 year.
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Patients and Methods
Study population
From January 2005 to December 2009, data regarding all epi-
sodes of PVGI treated in our referral centre were prospec-
tively collected. The majority of patients had their original
vascular surgery in other hospitals and were referred to our
centre.
In accordance with the French ethics law, approval of an
ethics committee was not required in such a cohort study,
which did not modify existing diagnosis or therapeutic strate-
gies. The database was completed at regular intervals.
Case definition of PVGI
Uniform criteria have not been established for the diagnosis
of PVGI. We used the definition proposed by FitzGerald
et al. [2]. A patient was considered as having definite PVGI if
two of the following three criteria were present: (i) positive
bacterial culture of intraoperative specimens or blood sam-
ples (for potential ‘contaminant’ pathogens, such as coagu-
lase-negative Staphylococcus, Propionibacterium acnes or
corynebacteria, at least two intraoperative specimens or
blood samples, or at least one intraoperative specimen and
one blood culture, were required); (ii) clinical signs of infec-
tion (general (fever, chills and septic shock) or in the area of
the prosthesis, e.g. inflammatory signs in the area of the vas-
cular graft—local pain, erythema or tumefaction, sinus tract
infection communicating with the PVGI, enteric aortic fistula,
intraoperative gross purulence or failure of graft consolida-
tion); and (iii) biological signs of infection (C-reactive protein
>10 mg/L, white blood count >10 000/mm3) or other radio-
logical signs of infection (perigraft air or fluid persisting for
more than 8 weeks postoperatively, abscess). Each case of
definite infection was classified as early-onset infection when
occurring within 4 months after surgery, or as late-onset
infection when occurring more than 4 months after surgery.
PVGI or stent infection was suspected when bacteraemia
related to a site other than the surgical site occurred in the
early postoperative period (within 4 weeks of graft or stent
implantation).
Risk factors for PVGI
Risk factors for PVGI were defined as the following: diabetes
mellitus as per an expert committee on diagnosis and classifi-
cation of diabetes mellitus [11]; chronic obstructive pulmo-
nary disease as per the American Thoracic Society [12];
obesity as body mass index ‡30 kg/m2 and overweight as
25 kg/m2 £body mass index <30 kg/m2; malnutrition as
£19 kg/m2 [13]; chronic renal failure defined according to
the value of creatinine clearance, determined by the Cockr-
oft–Gault equation [14]; and immunosuppression (e.g. steroid
therapy >7.5 mg/day, cancer, AIDS).
Microbiological assay
Blood specimens for culture were drawn from all febrile
patients (over 38.5C). Superficial samples (e.g. discharge
from fistula, compress or swab) were not used. Bacterial
samples were collected intraoperatively. Multiple intraopera-
tive samples were cultured on blood agar plates with stan-
dard aerobic and anaerobic methods. Antibiotic
susceptibility patterns were interpreted in accordance with
the recommendations of the Comite´ de l’Antibiogramme de
la Socie´te´ Franc¸aise de Microbiologie (www.sfm-microbiolo-
gie.org).
Vascular surgical management
In order to treat infection and to maintain or re-establish
vascular flow to the distal bed, the optimal surgical treat-
ment included complete debridement of devitalized and
infected tissues around the prosthesis, total graft excision
and in situ reconstruction with a new prosthesis, autogenous
vein or arterial allograft/homograft.
When such optimal management could not be realized
because of unfavourable local or general conditions, surgical
treatment could be limited to debridement without graft
excision or even contraindicated. In some cases, excised
graft could be replaced by extra-anatomical bypass grafting
or when peripheral perfusion was good, it could not be
replaced. Finally, when revascularization was not possible,
amputation was proposed to the patient.
Antimicrobial treatment
Empirical broad-spectrum antibiotic therapy was started
immediately after intraoperative sampling, and was secondar-
ily adapted to microbiological results. Nevertheless, in cases
of severe sepsis, empirical treatment was started before sur-
gical management, immediately after blood samples had been
collected.
Initial antimicrobial treatment was considered to be
appropriate when all causative pathogens were susceptible
in vitro to at least one of the antibiotics in the regimen. Anti-
biotic treatment duration depended on the vascular substi-
tute used to replace the infected prosthesis. In cases of
prosthetic vascular grafts or allografts/homografts, the dura-
tion of intravenous antibiotic treatment was 6 weeks,
followed by oral administration for a minimal duration of
6–12 months. Then, prolonged suppressive antimicrobial
therapy was proposed in immunocompromised patients or
very old patients with altered status. Prolonged suppressive
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antimicrobial therapy was also prescribed when the pro-
posed surgical procedure was refused by the patient or con-
traindicated. When autogenous vein grafts were used, the
duration of intravenous antimicrobial treatment was 3 weeks
without additional oral treatment.
Outcome assessment
Patient outcome was assessed during hospitalization, upon
completion of antibiotic treatment and during a long-term
follow-up ‡1 year. The parameters used to assess long-term
outcome included physical examination, signs of arterial dys-
function (arterial Doppler, computed tomography scan) and
laboratory tests (C-reactive protein and differential leukocyte
counts).
In-hospital patient mortality was defined as any death,
regardless of its cause, occurring during hospitalization in
our referral centre. Cure was defined as the absence of clini-
cal, biological and radiological evidence of infection during
the entire post-treatment follow-up for a minimum of 1 year.
Failure was defined as any other outcome.
Statistical analysis
Descriptive analyses were performed to check. Quantitative
variables are reported as means ± standard deviations. Qual-
itative variables are reported as number and percentage.
Continuous variables were compared by use of Student’s t-
test. Categorical variables were compared by use of the chi-
square test or Fisher’s exact test when the chi-square test
was not appropriate. Differences between groups were con-
sidered to be significant for variables yielding a p-value
£0.05. To determine independent variables associated with
prognosis, we performed a complete multivariate analysis,
including prognostic factors associated with a p-value <0.10
in bivariate analysis and, if clinically relevant, some forced
variables. Then, adjusted ORs were computed with a logistic
regression analysis including the independent predictors of
mortality. The fitness of the model and its predictive power
were assessed by the determination of the area under the
receiver operating characteristic curve. All statistical analyses
were performed with SAS Software, V9.1.
Results
Population
During the study period, 111 patients were prospectively
recruited. Twenty-six patients were excluded (insufficient
data collection or suspected PVGI). A total of 85 evaluable
patients with definite PVGI were included in this cohort. The
initial indication for vascular graft was aortic aneurysm
(n = 39) and/or lower limb arteriopathy (n = 58). The main
patient characteristics are summarized in Table 1.
Bacteriological data
Identification of the causative organism(s) was achieved in 78
(91.7%) patients. Preoperative blood cultures were positive
in 29 patients. Cultures of intraoperative samples were posi-
tive in 78 patients. Both cultures were positive in 18
patients. The distribution of causative microorganisms is
listed in Table 1. The only statistically significant difference
was the incidence of PVGI caused by Staphylococcus aureus,
which was greater in patient with limb PVGI.
Forty-three patients had antimicrobial agent(s) before the
intraoperative bacterial sampling. Thirty-eight of them
(88.4%) had positive cultures. Forty-two patients were trea-
ted immediately after the bacterial samples were taken, and
40 of them had positive cultures. This difference was not sta-
tistically significant (p 0.4).
Antimicrobial treatment and surgical procedures
Empirical antimicrobial treatment. In most patients, we used
antibiotic combinations, as follows: b-lactam + anti-methicil-
lin-resistant S. aureus (MRSA) agent, n = 39; b-lactam + anti-
MRSA agent + aminoglycoside, n = 21; and others, n = 25.
Culture-guided antibiotic treatment. Initial empirical treatment
was appropriate in 75 of 85 patients (88.2%). De-escalation
was carried out for 72 patients, according to the suscepti-
bility of the microorganisms. Among the 71 patients surviv-
ing to initial hospitalization, 57 were discharged with
antibiotics administered by the oral route: 23 were treated
with an oral rifampin combination, 25 with a fluoroquino-
lone used in combination or alone, and nine with various
oral agents.
Duration of antimicrobial treatment. In the 71 patients surviving
initial hospitalization, the complete duration of antibiotic
treatment was 156 ± 94 days (49 ± 45 days for the intra-
venous form).
Twenty-two patients received suppressive antimicrobial
therapy after complete treatment, consisting of doxycyclin or
minocyclin (n = 18) and fluoroquinolones (n = 4).
Initial surgical treatment
Surgery (Fig. 1) was performed in 75 of 85 patients (88.23%).
In 41 patients, this treatment was optimal, with graft excision
and replacement of the infected prosthesis by autologous
vein (n = 13), prosthetic conduit (n = 12) or allograft/homo-
graft (n = 16). In 34 patients, only debridement of the pros-
thetic graft was performed. No extra-anatomical bypass was
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performed. No initial major amputations were performed. In
ten patients, no surgery was performed.
Outcome
During the immediate postoperative period, 40 patients were
admitted to an intensive-care unit (ICU). Indications for ICU
admission were aortic PVGI (n = 27) and/or the occurrence
of septic shock during the surgical procedure (n = 17).
A second surgical procedure was necessary for 28 patients
during the same hospital stay, because of graft rupture (n = 9),
graft thrombosis (n = 9), persistent or recurrent infection
(n = 25) or limb ischaemia (n = 1). Among these patients, the
vascular device was removed in 14 and replaced. One patient
required major amputation above the knee.
Fourteen patients (16.5%) with PVGI died during the initial
hospitalization. Mortality rates were 22.2% and 6.5% in aortic
and limb PVGI, respectively (p 0.06). The mean delay to
death was 27 ± 25 days from the beginning of hospitalization.
Data concerning the in-hospital outcome are summarized in
Fig. 1. Most deaths occurred in the ICU (n = 12) as a direct
consequence of the PVGI: haemorrhagic shock (n = 6), septic
shock (n = 5) or mesenteric ischaemia (n = 1). The two
remaining deaths were caused by intestinal occlusion (n = 1)
and cardiac arrhythmia (n = 1). There were no intraopera-
tive deaths.
In multivariate analysis (Table 2), we entered four vari-
ables identified by bivariate analysis as listed in Table 3 and
one forced variable according to its clinical importance (sur-
gical debridement with excision of the infected graft). We
did not enter significant variables when they were related to
a low number of patients or when their association with
prognosis was biased. Two independent prognostic variables
were identified: age >70 years and aortic graft infection. The
fitness of the model was 0.78.
Follow-up period. Fifty-nine of 71 patients surviving to the ini-
tial hospitalization were evaluable after a minimum follow-up
of 1 year. Overall cure was observed in 93.2% of 59 evalu-
TABLE 1. Characteristics of the population studied and bacteriological data according to delay and to the localization of pros-
thetic vascular graft infection (PVGI)
Characteristics
Early PVGI
(n = 49)
Late PVGI
(n = 36) p-value
Aortic PVGI
(n = 54)
Limb PVGI
(n = 31) p-value
Men 43 (87.7) 31 (86.1) 0.82 50 (92.6) 24 (77.4) 0.04
Age (years) 67.8 ± 12.2 67.9 ± 10.9 0.99 66.2 ± 12.2 70.8 ± 10.1 0.07
Diabetes mellitus 16 (32.6) 8 (22.2) 0.29 13 (24) 11 (35.5) 0.26
Chronic obstructive pulmonary
disease
10 (20.4) 6 (16.6) 0.66 12 (22.2) 4 (12.9) 0.40
Obesity, overweight 33 (67.3) 17 (47.2) 0.06 31 (57.4) 19 (61.3) 0.73
Malnutrition 2 (4) 3 (8.3) 0.65 4 (7.4) 1 (3.2) 0.65
Severe renal insufficiency 4 (8) 3 (8.3) 1 5 (9.2) 2 (6.4) 1
Immunosuppression 7 (14.3) 4 (11.1) 0.75 6 (11.1) 5 (16.1) 0.52
Coronary artery disease 22 (44.8) 22 (61.1) 0.14 31 (57.4) 13 (41.9) 0.17
Arterial hypertension 37 (75.5) 29 (80.5) 0.58 39 (72.2) 27 (87.1) 0.11
Fever 38 (77.5) 19 (52.7) 0.01 38 (70.3) 19 (61.3) 0.51
Local erythema 32 (65.3) 15 (41.6) 0.02 23 (42.6) 24 (77.4) 0.001
Fistula discharge 27 (55.1) 20 (55.5) 0.95 24 (44.4) 23 (74.1) 0.004
Abdominal pain 12 (24.5) 7 (19.4) 0.58 15 (27.7) 4 (12.9) 0.11
Gastrointestinal bleeding 0 (0) 2 (5.5) 1 2 (3.7) 0 (0) 1
White blood count (/mm3) 13 030 ± 6711 9780 ± 3140 0.14 12 112 ± 6145 10 355 ± 4089 0.35
C-reactive protein (mg/L) 136 ± 79 94 ± 80 0.05 133 ± 92 89 ± 50 0.04
False aneurysm 6 (14.3) 1 (3.1) 0.23 2 (4) 5 (20.8) 0.09
Graft rupture 7 (16.6) 3 (9.3) 0.51 7 (14) 3 (12.5) 0.74
Graft thrombosis 4 (9.5) 7 (2.2) 0.19 7 (14) 4 (16.6) 1
Perigraft fluid/air/abscess 34 (80.9) 31 (96.8) 0.07 44 (81.5) 21 (87.5) 0.15
Positive blood samples 20 9 0.13 22 7 0.09
Polymicrobial infection 12 8 0.81 12 8 0.71
Number of microorganisms
isolated
63 41 64 40
Gram-positive bacteria 35 (55.5) 22 (53.6) 0.85 34 (53.1) 23 (57.5) 0.66
Staphylococcus aureus 20 (40.8) 9 (21.9) 0.28 12 (18.7) 17 (42.5) 0.009
Coagulase-negative
Staphylococcus
8 (12.7) 5 (12.2) 0.82 10 (15.6) 3 (7.5) 0.36
Enterococcus sp. 4 (6.3) 3 (7.3) 1 5 (7.8) 2 (5) 0.70
Streptococcus sp. 3 (4.7) 4 (9.7) 0.43 6 (9.3) 1 (2.5) 0.24
Other Gram-positive
bacteria
0 (0) 1 (2.4) 0.39 1 (1.5) 0 (0) 1
Gram-negative bacilli 20 (31.7) 15 (36.6) 0.61 21 (32.8) 14 (35) 0.82
Enterobacteriacae 19 (30.1) 13 (31.7) 0.87 20 (31.2) 12 (30) 0.89
Pseudomonas sp. 1 (2) 2 (4.8) 0.56 1 (1.5) 2 (5) 0.56
Anaerobes 6 (12.2) 2 (4.8) 0.47 6 (9.3) 2 (5) 0.71
Candida sp. 2 (2) 2 (4.8) 0.65 3 (4.6) 1 (2.5) 1
No growth 2 (4.1) 5 (13.8) 0.13 6 (9.3) 1 (2.5) 0.41
Data are expressed as n (%) or mean ± standard deviation.
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able patients. The others died because of new or recurrent
infection. None had limb graft infection.
Discussion
In the present study, the overall in-hospital mortality rate
among patients with PVGI was 16.5%. Moreover, there was
only one major amputation related to graft thrombosis.
Finally, overall cure was observed in 93.2% of the 59 patients
evaluable after a minimum follow-up of 1 year.
The in-hospital mortality rate of our cohort was similar to
rates reported in other series including patients treated with
in situ revascularization (6–21%) [15–18]. Recently, a meta-
analysis of in situ replacement methods reported by O’Con-
nor et al. [7] found that in situ replacement for aortic graft
infection prior to 1985 seemed to be more effective than
extra-anatomical bypass in terms of rates of early mortality
(0–16% vs. 1–51%) and of amputation (0–3% vs. 1–24%).
In our cohort, independent prognostic factors for in-hos-
pital mortality included age >70 years and aortic PVGI. In
the literature, some other factors have been identified.
These were urgent operation, post-operative complications,
intra-thoracic localization and at least, debridement with
retention of vascular grafts [3–5,15,19]. This last factor was,
in our series, clearly without any significant impact on prog-
nosis. In patients with aortic PVGI, we did not identify spe-
cific risk factors, whereas Armstrong et al. [9] found three
Initial treatment option Final treatment option*  
In-hospital 
mortality n (%)
Antimicrobial 
treatment 
without surgery 
n = 1
Antimicrobial treatment 
without surgery n = 1 0 (0%)
Limb 
PVGI 
   n = 31   
Surgical 
treatment n = 30  
Debridement and 
removal 
  prosthesis n = 18   
Debridement and
removal prosthesis
n = 22   
2 (9%)
Debridement
without removal
prosthesis n = 12   
Debridement without 
removal prosthesis n = 8  0 (0%)
Population
studied
n = 85   
Antimicrobial treatment
without surgery n = 8  
2 (25%)
Antimicrobial
treatment
without surgery
n = 9    
Debridement and
removal prosthesis n = 1  0 (0%)
Aortic
PVGI
   n = 54   
Surgical
treatment n = 45  
Debridement and
removal
prosthesis n = 23   
Debridement and
removal prosthesis
n = 27  
6 (22.2%)
Debridement
without removal
prosthesis n = 22
Debridement without
removal prosthesis
n = 18   
4 (22.2%)
FIG. 1. In-hospital mortality according to the
localization of prosthetic vascular graft infec-
tion (PVGI) and the treatment option. *Only
patients who were initially treated with
debridement without removal of prosthesis
and who needed a new operation consisting
of replacement with a new vascular substitute
were counted. The others who were initially
treated with debridement with removal of
prosthesis and who needed a replacement
with a new vascular substitute were not
counted.
TABLE 2. Multivariate analysis of risk factors for in-hospital
mortality
Variable OR (95% CI) p-value
Complete model
Aortic graft infection 9.17 (1.42–58.87) 0.02
Early-onset infection 0.34 (0.09–1.36) 0.13
Age >70 years 10.74 (1.76–65.48) 0.01
PVGI caused by Gram-negative bacilli 2.41 (0.58–9.98) 0.22
Surgical debridement with excision
of infected graft
2.84 (0.62–13.0) 0.18
Logistic procedure
Aortic graft infection 5.6 (1.1–28.7) 0.037
Age >70 years 9.1 (1.83–45.43) 0.007
PVGI, prosthetic vascular graft infection.
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variables that were significantly associated with fatal out-
come: shock at presentation, preoperative transfusion, and
use of suprarenal aortic clamping during aorto-enteric fistula
repair.
Although such observation were not made in our series,
we must underline the fact that some authors reported a less
favourable outcome with PVGI caused by MRSA, Pseudomonas
species and Gram-negative bacilli, with a predisposition for
prosthetic anastomosis disruption. However, there are no
data on the antimicrobial agents used in those studies [20,21].
The present study had several limitations. Potential bias
might result from the variety of surgical approaches, the
inclusion of aortic and limb PVGI in the same analysis, delay
to surgical procedure and the selection of our patients trea-
ted in a referral centre. However, we included patients with
a homogeneous definition of PVGI and treated via homoge-
neous approaches, and we performed a long-term follow-up.
We suggest that patients with PVGI should be managed at
referral centres, owing to the high risk of perioperative
death and amputation along with re-infection. Although most
patients included in the present study and treated with previ-
ous antibiotic therapy had intraoperative positive samples, all
efforts should be made to isolate causative organism(s) by
repeated blood cultures and culture of abscesses or intraop-
erative samples, following an adequate wash-out period of
previously administered antibiotics when feasible. Because of
the weak correlation between microbiology and localization
of PVGI [2,6], empirical treatment should cover Gram-posi-
tive cocci, including MRSA, Gram-negative bacilli and anaer-
obes. As soon as positive culture results are available,
antibiotic treatment should be gradually lowered and adapted
to the results of bacterial susceptibility testing. However, no
consensus exists on the preferable classes of agent, and the
best appropriate initial empirical treatment is still unknown.
On the basis of our experience in managing valvular prosthe-
ses and orthopaedic infections [22–28], we feel that the use
of antimicrobial agents such as rifampin, quinolones or dapto-
mycin (especially for infection caused by Gram-positive
cocci) [29,30], combined with optimal surgical treatment and
followed by long-term antibiotic therapy, is the key compo-
nent of successful treatment. Finally, to limit both the risk of
bacterial adhesion to vascular devices and the risk of new or
persistent infection, in situ arterial allograft or autogenous
vein reconstruction is preferable to standard prostheses in
selected patients [7].
In conclusion, because of the creation of a multidisciplin-
ary group for the management of PVGI, the mortality rate
was similar to that in the literature. Age >70 years and aor-
tic graft infection were independent risk factors associated
with in-hospital mortality in these patients.
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